BioSpace News Archive

Drug Development

Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

Duvelisib Achieves Overall Response Rate of 62% in Patients with Relapsed or Refractory PTCL with Manageable Safety Profile in Initial Phase of PRIMO Trial

December 7, 2019
·
16 min read
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019

Oncopeptides AB will present follow-up data from the pivotal Phase 2 HORIZON study at the ASH Annual Meeting 2019.

December 7, 2019
·
5 min read
Drug Development

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis

Oral Presentation at the American Society of Hematology (ASH) Annual Meeting on December 7, 2019

December 7, 2019
·
16 min read
Deals

XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen

December 7, 2019
·
6 min read
Business

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma

Results from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)

December 7, 2019
·
11 min read
Business

IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia

Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were maintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)

December 7, 2019
·
17 min read
Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th

December 7, 2019
·
7 min read
Drug Development

Corvus Pharmaceuticals Presents Preclinical and Initial Clinical Data from the Phase 1/1b Trial of CPI-818 at the American Society of Hematology (ASH) Annual Meeting

Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy

December 7, 2019
·
7 min read
Drug Development

Axcella Presents Data at ASH Annual Meeting

Preclinical mechanistic data for constituents of AXA4010 demonstrate multifactorial potential of endogenous metabolic modulators (EMMs) on red blood cell, immune and vascular health

December 7, 2019
·
6 min read
Biotech Bay

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, announced new results from the hematological portion of the ALX148 Phase 1 program at the 2019 ASH Annual Meeting.

December 7, 2019
·
4 min read